These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31903424)

  • 1. The Costs of Implementing Vaccination With the RTS,S Malaria Vaccine in Five Sub-Saharan African Countries.
    Sicuri E; Yaya Bocoum F; Nonvignon J; Alonso S; Fakih B; Bonsu G; Kariuki S; Leeuwenkamp O; Munguambe K; Mrisho M; Were V; Sauboin C
    MDM Policy Pract; 2019; 4(2):2381468319896280. PubMed ID: 31903424
    [No Abstract]   [Full Text] [Related]  

  • 2. Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries.
    Baral R; Levin A; Odero C; Pecenka C; Tabu C; Mwendo E; Bonsu G; Bawa J; Dadzie JF; Charo J; Antwi-Agyei KO; Amponsa-Achianou K; Jalango RE; Mkisi R; Gordon S; Mzengeza T; Morgan W; Muhib F
    PLoS One; 2021; 16(1):e0244995. PubMed ID: 33428635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program.
    Baral R; Levin A; Odero C; Pecenka C; Tanko Bawa J; Antwi-Agyei KO; Amponsa-Achaino K; Chisema MN; Eddah Jalango R; Mkisi R; Gordon S; Morgan W; Muhib F
    Vaccine; 2023 Feb; 41(8):1496-1502. PubMed ID: 36710234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Policy uptake and implementation of the RTS,S/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation.
    Osoro CB; Ochodo E; Kwambai TK; Otieno JA; Were L; Sagam CK; Owino EJ; Kariuki S; Ter Kuile FO; Hill J
    BMJ Glob Health; 2024 Apr; 9(4):. PubMed ID: 38688566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costing RTS,S introduction in Burkina Faso, Ghana, Kenya, Senegal, Tanzania, and Uganda: A generalizable approach drawing on publicly available data.
    Galactionova K; Bertram M; Lauer J; Tediosi F
    Vaccine; 2015 Nov; 33(48):6710-8. PubMed ID: 26518406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RTS,S/AS01 malaria vaccine pilot implementation in western Kenya: a qualitative longitudinal study to understand immunisation barriers and optimise uptake.
    Hoyt J; Okello G; Bange T; Kariuki S; Jalloh MF; Webster J; Hill J
    BMC Public Health; 2023 Nov; 23(1):2283. PubMed ID: 37980467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.
    Galactionova K; Tediosi F; Camponovo F; Smith TA; Gething PW; Penny MA
    Vaccine; 2017 Jan; 35(1):53-60. PubMed ID: 27890400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation strategies for the introduction of the RTS,S/AS01 (RTS,S) malaria vaccine in countries with areas of highly seasonal transmission: workshop meeting report.
    Merle CS;
    Malar J; 2023 Aug; 22(1):242. PubMed ID: 37612716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of the Incremental Costs of Implementing a New Vaccine in the Expanded Program of Immunization in Sub-Saharan Africa.
    Brew J; Sauboin C
    MDM Policy Pract; 2019; 4(2):2381468319894546. PubMed ID: 31903423
    [No Abstract]   [Full Text] [Related]  

  • 10. Estimated impact of RTS,S/AS01 malaria vaccine allocation strategies in sub-Saharan Africa: A modelling study.
    Hogan AB; Winskill P; Ghani AC
    PLoS Med; 2020 Nov; 17(11):e1003377. PubMed ID: 33253211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estimating the costs of the vaccine supply chain and service delivery for selected districts in Kenya and Tanzania.
    Mvundura M; Lorenson K; Chweya A; Kigadye R; Bartholomew K; Makame M; Lennon TP; Mwangi S; Kirika L; Kamau P; Otieno A; Murunga P; Omurwa T; Dafrossa L; Kristensen D
    Vaccine; 2015 May; 33(23):2697-703. PubMed ID: 25865467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Impact of Introducing the RTS,S Malaria Vaccine: Cost-Effectiveness and Budget Impact Analysis in 41 Countries.
    Sauboin C; Van Bellinghen LA; Van De Velde N; Van Vlaenderen I
    MDM Policy Pract; 2019; 4(2):2381468319873324. PubMed ID: 31853505
    [No Abstract]   [Full Text] [Related]  

  • 13. How much does it cost to get a dose of vaccine to the service delivery location? Empirical evidence from Vietnam's Expanded Program on Immunization.
    Mvundura M; Kien VD; Nga NT; Robertson J; Cuong NV; Tung HT; Hong DT; Levin C
    Vaccine; 2014 Feb; 32(7):834-8. PubMed ID: 24370713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current challenges and proposed solutions to the effective implementation of the RTS, S/AS01 Malaria Vaccine Program in sub-Saharan Africa: A systematic review.
    Dimala CA; Kika BT; Kadia BM; Blencowe H
    PLoS One; 2018; 13(12):e0209744. PubMed ID: 30596732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness and public health impact of RTS,S/AS01
    Ndeketa L; Mategula D; Terlouw DJ; Bar-Zeev N; Sauboin CJ; Biernaux S
    Wellcome Open Res; 2020; 5():260. PubMed ID: 34632084
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa.
    Guerra Mendoza Y; Garric E; Leach A; Lievens M; Ofori-Anyinam O; Pirçon JY; Stegmann JU; Vandoolaeghe P; Otieno L; Otieno W; Owusu-Agyei S; Sacarlal J; Masoud NS; Sorgho H; Tanner M; Tinto H; Valea I; Mtoro AT; Njuguna P; Oneko M; Otieno GA; Otieno K; Gesase S; Hamel MJ; Hoffman I; Kaali S; Kamthunzi P; Kremsner P; Lanaspa M; Lell B; Lusingu J; Malabeja A; Aide P; Akoo P; Ansong D; Asante KP; Berkley JA; Adjei S; Agbenyega T; Agnandji ST; Schuerman L
    Hum Vaccin Immunother; 2019; 15(10):2386-2398. PubMed ID: 31012786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term incidence of severe malaria following RTS,S/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial.
    Tinto H; Otieno W; Gesase S; Sorgho H; Otieno L; Liheluka E; Valéa I; Sing'oei V; Malabeja A; Valia D; Wangwe A; Gvozdenovic E; Guerra Mendoza Y; Jongert E; Lievens M; Roman F; Schuerman L; Lusingu J
    Lancet Infect Dis; 2019 Aug; 19(8):821-832. PubMed ID: 31300331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost of introducing and delivering malaria vaccine (RTS,S/AS01
    Diawara H; Bocoum FY; Dicko A; Levin A; Lee C; Koita F; Ouédraogo JB; Guissou R; Yabré S; Traoré S; Morgan W; Pecenka C; Baral R
    BMJ Glob Health; 2023 Apr; 8(4):. PubMed ID: 37068848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
    Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
    Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Malaria vaccine coverage estimation using age-eligible populations and service user denominators in Kenya.
    Moturi AK; Jalang'o R; Cherono A; Muchiri SK; Snow RW; Okiro EA
    Malar J; 2023 Sep; 22(1):287. PubMed ID: 37759277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.